AGÕæÈ˹ٷ½

STOCK TITAN

[SCHEDULE 13G] Mural Oncology plc SEC Filing

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13G
Rhea-AI Filing Summary

DocuSign, Inc. (DOCU) â€� Insider Activity Filing (Form 4)

Chief Financial Officer Blake Jeffrey Grayson reported two open-market sales of DocuSign common stock on 18 June 2025 executed under a pre-arranged Rule 10b5-1 trading plan.

  • Total shares sold: 15,143 (13,208 at $74.27-$75.22 and 1,935 at $75.33-$75.63).
  • Estimated gross proceeds: â‰� $1.13 million.
  • Remaining beneficial ownership: 110,723 shares held directly.
  • No derivative transactions or new option grants were reported.

The filing reflects routine diversification by the CFO while maintaining a substantial equity stake, limiting potential governance concerns. Investors may monitor subsequent insider activity to assess sentiment trends.

Positive
  • Continued insider ownership: CFO retains 110,723 shares, signalling ongoing alignment with shareholders.
  • Use of Rule 10b5-1 plan: Adherence to pre-planned trading reduces information-asymmetry concerns.
Negative
  • Insider share sale: Disposal of 15,143 shares by a key executive could be interpreted as reduced confidence despite pre-planning.

Insights

TL;DR: Pre-planned sale by CFO; routine, minor governance impact, modest signalling risk.

The transaction was executed under a Rule 10b5-1 plan, reducing the risk of information-based trading and aligning with best-practice governance standards. Although 15,143 shares were sold, the CFO still holds roughly 111k shares, preserving meaningful skin in the game. The dollar value (~$1.1 m) is immaterial relative to DocuSign’s market capitalisation, so I view the action as normal liquidity management rather than a negative signal.

TL;DR: Neutral market impact; selling volume <0.1 % of float, under 10b5-1.

Insider sales can pressure sentiment, but volume here is negligible versus DOCU’s average daily volume (~3-4 m shares). Because trades are rule-driven and clustered in one day, I expect minimal pricing effect. With the CFO retaining over 110k shares, long-term alignment remains. Watch for follow-up filings from other executives for any pattern change.






Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)






SCHEDULE 13G




Comment for Type of Reporting Person: The figure in Item 11 is based upon 17,268,881 Ordinary Shares, nominal value $0.01 per share ("Ordinary Shares") of Mural Oncology plc (the "Issuer") outstanding as of May 1, 2025, as disclosed in the Issuer's quarterly report on Form 10-Q for the quarterly period ended March 31, 2025, filed with the U.S. Securities and Exchange Commission (the "SEC") on May 14, 2025.


SCHEDULE 13G




Comment for Type of Reporting Person: The figure in Item 11 is based upon 17,268,881 Ordinary Shares of the Issuer outstanding as of May 1, 2025, as disclosed in the Issuer's quarterly report on Form 10-Q for the quarterly period ended March 31, 2025, filed with the SEC on May 14, 2025.


SCHEDULE 13G




Comment for Type of Reporting Person: The figure in Item 11 is based upon 17,268,881 Ordinary Shares of the Issuer outstanding as of May 1, 2025, as disclosed in the Issuer's quarterly report on Form 10-Q for the quarterly period ended March 31, 2025, filed with the SEC on May 14, 2025.


SCHEDULE 13G




Comment for Type of Reporting Person: The figure in Item 11 is based upon 17,268,881 Ordinary Shares of the Issuer outstanding as of May 1, 2025, as disclosed in the Issuer's quarterly report on Form 10-Q for the quarterly period ended March 31, 2025, filed with the SEC on May 14, 2025.


SCHEDULE 13G




Comment for Type of Reporting Person: The figure in Item 11 is based upon 17,268,881 Ordinary Shares of the Issuer outstanding as of May 1, 2025, as disclosed in the Issuer's quarterly report on Form 10-Q for the quarterly period ended March 31, 2025, filed with the SEC on May 14, 2025.


SCHEDULE 13G



Prosight Management, LP
Signature:Prosight Partners, LLC
Name/Title:General Partner
Date:06/26/2025
Signature:/s/ W. Lawrence Hawkins
Name/Title:Sole Manager of the General Partner
Date:06/26/2025
Prosight Fund, LP
Signature:Prosight Management, LP
Name/Title:General Partner
Date:06/26/2025
Signature:Prosight Partners, LLC
Name/Title:Sole Manager of the General Partner
Date:06/26/2025
Signature:/s/ W. Lawrence Hawkins
Name/Title:Sole Manager of the General Partner of the General Partner
Date:06/26/2025
Prosight Plus Fund, LP
Signature:Prosight Management, LP
Name/Title:General Partner
Date:06/26/2025
Signature:Prosight Partners, LLC
Name/Title:General Partner of the General Partner
Date:06/26/2025
Signature:/s/ W. Lawrence Hawkins
Name/Title:Sole Manager of the General Partner of the General Partner
Date:06/26/2025
Prosight Partners, LLC
Signature:/s/ W. Lawrence Hawkins
Name/Title:Sole Manager
Date:06/26/2025
W. Lawrence Hawkins
Signature:/s/ W. Lawrence Hawkins
Name/Title:W. Lawrence Hawkins
Date:06/26/2025
Exhibit Information

Exhibit 99.1: Joint Filing Agreement (filed herewith).

FAQ

How many DocuSign shares did CFO Blake Grayson sell on 18 June 2025?

He sold 15,143 shares of DOCU common stock in two separate transactions.

At what price range were the DOCU shares sold?

Shares were sold between $74.27 and $75.63 per share.

Does the CFO still hold DocuSign shares after the sale?

Yes, Blake Grayson continues to own 110,723 shares directly.

Was the insider sale under a Rule 10b5-1 trading plan?

Yes. The filing states the transactions were executed pursuant to a Rule 10b5-1 plan adopted earlier.

Is this Form 4 likely to impact DOCU’s stock price?

Given the small size relative to daily volume and pre-planning, analysts view the impact as neutral to minimal.
Mural Oncology PLC

NASDAQ:MURA

MURA Rankings

MURA Latest News

MURA Latest SEC Filings

MURA Stock Data

40.06M
15.01M
13.07%
57.4%
1.35%
Biotechnology
Pharmaceutical Preparations
Ireland
DUBLIN 2